NEWS
7 March 2024
Paddington Life Sciences featured at health technology event
Vodafone and Microsoft were among the Paddington Life Sciences partners represented at an event exploring ways to support the adoption of innovative new technology in the NHS.
Last year, the Shelford Group and the ABHI, the UK’s leading HealthTech trade association, committed to a joint programme to offer solutions to some of the biggest challenges impacting the NHS. Imperial College Healthcare is the first in the Shelford Group to host an event as part of this programme.
The event’s focus was on building awareness and understanding of how successful partnerships between NHS, communities, academia, and industry can support the development of technologies that meet the needs of patients and the NHS. Discussions also explored how to accelerate the uptake and spread of research and innovation. Over 40 health technology companies were among the attendees.
Opening the event, Professor Tim Orchard, chief executive of Imperial College Healthcare NHS Trust and chair of the Shelford Group, said: “There's a constant debate about how the NHS can be a better partner to organisations developing technologies that address the needs of the NHS. We're hoping this will be the first in a series of events to build stronger relationships between the NHS and industry and support the development of technologies that are of real use to our patients and the NHS.”
Peter Ellingworth, chief executive of the ABHI, who also spoke at the event, said: “Whether you’re in the NHS or industry, we need to gain a better understanding of each other. A big opportunity lies in understanding each other to a level of intensity that lets us run our businesses and health systems with real purpose and change that overcomes inertia.”
Through a series of panel discussions, the event showcased some of the Trust’s areas of strength for engagement with the health technology industry, including digital health, the National Institute for Health and Care Research (NIHR) Imperial Biomedical Research Centre (BRC), and community partnerships.
The event was also an opportunity to explore some of the wider considerations and challenges of health technology innovation in the UK, with a focus on the increased regulatory challenges facing the industry.
Unlocking the value of data and digital
Mr Erik Mayer, the NIHR Imperial BRC digital health theme lead and director of iCARE and the Digital Collaboration Space, chaired a discussion of examples and key learnings from existing digital health partnerships to enable the use of artificial intelligence in healthcare. This included using AI to improve both clinical and administrative efficiency and deliver improved outcomes. The panel included Dr Umang Patel, chief clinical information officer at Microsoft, who are a member of Paddington Life Sciences Partners.
The vital role of the NIHR Imperial BRC in supporting the translation of medical technology was emphasised in a panel discussion chaired by Professor Mark Thursz, director of the NIHR Imperial BRC. This partnership between the Trust and Imperial College London was awarded £95.3 million investment by the NIHR in 2022 to continue developing new experimental treatments and diagnostics for patients.
Senior BRC researchers showcased examples of how this research infrastructure can work with industry to accelerate the translation of new research, including the ORBITA-2 trial exploring the effect of heart stents, and the TRICORDER programme using AI stethoscopes to diagnose heart failure.
Collaboration to create value
The importance of how partnerships between the NHS and industry can help deliver social, health and commercial value was emphasised in a discussion led by Professor Bob Klaber, Imperial College Healthcare director of strategy, research and innovation.
The discussion drew on examples from the Trust’s Paddington Life Sciences development, which aims to create a thriving ecosystem for life sciences research and innovation in north west London. As part of this, the Trust is working with several local partners on projects that aim to deliver social value to local communities in Paddington. The panel included Nicola Mortali regional director for Vodafone in Health, who are a member of Paddington Life Sciences Partners.
Speaking on the next steps, Professor Bob Klaber, said: “This event discussion around how we best move forward with our research, innovation and life sciences work as an organisation, in partnership with the College, and with industry as a wider system, contributed very fully to what felt like a productive day. The ultimate test of that will be from the impact of the collaborations and partnerships that we hope will follow from it.”